News

Ampyra (dalfampridine) shows long-term efficacy in improving walking ability in people with multiple sclerosis, according to a study evaluating the treatment’s use in progressive and relapsing MS patients over two years. The study, “Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis,” was published in the…

Multiple Sclerosis News Today interviewed Dr. Linard Filli,
 an MS researcher at the University Hospital Zurich involved in clinical studies of prolonged release Ampyra (dalfampridine), on walking ability in MS patients, and Dr. Andrew Blight, chief scientific officer at Acorda Therapeutics, the treatment’s developer. Here is a full transcript of that interview. An…

More than 2,000 bicyclists are expected to join in the 30th Annual Running of the Bike MS: Sam’s Club Round-Up Ride, set for May 6-7 in Fort Worth, Texas. The two-day, 163-mile trek’s objective is to raise $1.8 million in funding for people living with multiple sclerosis (MS). Last year, participants pedaled 279,000 miles…

Three Canadian entities — Toronto-based Biogen Canada and the MS Society of Canada, and Montreal-based Brain Canada — have jointly invited researchers to establish a multiple sclerosis (MS) progression cohort in Canada. The $7 million nationwide MS Progression Cohort offers a timely opportunity to investigate some of the biggest challenges in curing progressive MS, such as…

The use of antibiotics in childhood, which alters the microbiome — or natural bacteria flora in the gut — may increase the risk of multiple sclerosis (MS), inflammatory bowel disease (IBD) and other inflammatory diseases, according to an Australian study. The mouse study, “Early-life antibiotic treatment enhances the…

Ocrevus (ocrelizumab), now approved for both relapsing and primary progressive multiple sclerosis (MS), is expected to become available in the coming week. While patients and neurologists are waiting, Multiple Sclerosis News Today spoke to Genentech about the treatment’s approval, future research plans, and what patients can expect in terms…

Nektar Therapeutics has started a Phase 1 clinical trial of its biologic therapy NKTR-358 for inflammatory disorders and autoimmune diseases like multiple sclerosis. NKTR-358 is a first-in-class regulatory T-cell stimulator designed to correct the immune system dysfunction associated with these disorders. It targets regulatory T-cells, or Tregs. Other immunosuppressant therapies suppress the…

Dr. Stephen Hauser, chair of the neurology department at the University of California San Francisco, was instrumental in the early research and later clinical trials that ultimately led to Ocrevus (ocrelizumab), the first therapy approved by the U.S. Food and Drug Administration (FDA) for both relapsing MS (RMS) and primary progressive multiple sclerosis…

Scientists at the University of Maryland have developed an experimental treatment to control the immune system and recover movement in a paralyzed mouse model of multiple sclerosis (MS). The team presented its research April 2 during the 253rd National Meeting & Exposition of the American Chemical Society in San Francisco. In…

Here is a transcript of the Multiple Sclerosis News Today interview about Ocrevus (ocrelizumab) with Dr. Robert Lisak of the Consortium of Multiple Sclerosis Centers (CMSC). Lisak, a professor of neurology and of immunology and microbiology at Wayne State University School of Medicine, is a former…

Interest in  Ocrevus (ocrelizumab), the first FDA-approved treatment for both relapsing and primary progressive multiple sclerosis, is running high among patients and the organization representing them — as, arguably, are expectations of its use. But how do physicians involved in MS care view the newcomer? Dr. Robert Lisak (Photo courtesy…

Brain stem cells from primary progressive multiple sclerosis (PPMS) patients lack the ability to repair brain damage and to trigger the maturation of protective myelin-producing cells, a surprising study with far-reaching implications indicates. The study also showed that stem cells from individual patients reacted differently to compounds developed to trigger…

With the recent approval of Ocrevus (ocrelizumab) for both primary progressive and relapsing multiple sclerosis (MS), interest in the medication is peaking. To help readers of Multiple Sclerosis News Today better understand this new medication and how it works, as well issues dealing with access, use, and potential side effects, here is a summary…

British scientists have accelerated from weeks to days the process by which stem cells generate brain cells, which could open the door to new treatment approaches for diseases such as multiple sclerosis. Researchers at the Wellcome Trust Sanger Institute and colleagues at the University of Cambridge developed the…

Diplomat Pharmacy, the largest independent specialty pharmacy in the U.S., has been selected to dispense Ocrevus (ocrelizumab), a limited-distribution drug, to people with relapsing  and primary progressive multiple sclerosis. Ocrevus was approved by the U.S. Food and Drug Administration on March 28, becoming the first therapy approved for both RMS and…

As the challenge of living with multiple sclerosis (MS) often leaves patients feeling isolated and depressed, the biopharmaceutical firm EMD Serono has launched an online storytelling platform called My Story. The platform is designed to be an empowering and therapeutic support resource for patients and caregivers in their struggles with MS.

Using a small RNA molecule belonging to the family of microRNAs (miRs), scientists could restore myelin in nerve cells and improve limb function in mouse models of human multiple sclerosis (MS). The study, “miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS,” was published in…

American patient groups and neurologists have clearly been giving Ocrevus (ocrelizumab) plenty of attention since news of its approval landed, as a sweep of U.S. reaction to the FDA’s decision showed. But what is happening elsewhere in regard to this first treatment for both primary progressive and relapsing multiple sclerosis (MS)?…

The historic approval of Ocrevus (ocrelizumab), the first-ever treatment for primary progressive multiple sclerosis (MS), set off ripples in the relatively calm waters of MS news reporting. The drug, which was also approved Tuesday as an unusually effective and safe treatment for relapsing MS, is viewed as a game-changer…

Mothers with chronic inflammatory and autoimmune diseases, such as multiple sclerosis, have a higher risk of having children with attention-deficit/hyperactivity disorder (ADHD), according to a Norwegian study. The findings were reported in a study titled “Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases”…

At long last, and for the first time in medical history, people with both relapsing and primary progressive forms of multiple sclerosis have reason to celebrate. The U.S. Food and Drug Administration (FDA) today approved Ocrevus (ocrelizumab)  as a disease-modifying therapy for both forms of MS, a chronic autoimmune disease.

CGEN-15001, which could become the first tolerance-inducing therapy for multiple sclerosis (MS) and other autoimmune conditions, is on the agenda of a scientific conference in Canada that is going on now and another conference in May. The first CGEN-15001 presentation that Compugen is delivering is at the Keystone Symposia: Immune Regulation in Autoimmunity and…

Twenty years ago, the idea that B-cell depletion could treat multiple sclerosis would have been greeted with a hearty laugh by any well-respected neurologist or MS researcher — or perhaps a scoff. But times change and research advances. Today, a medicine that gets rid of certain B-cells may be the most powerful drug yet developed against…

High levels of a protein called Rab32 may contribute to the progression of multiple sclerosis (MS), leading to neuronal loss, a new study concludes. The study, “Rab32 connects ER stress to mitochondrial defects in multiple sclerosis,” appeared in the Journal of Neuroinflammation. The endoplasmic reticulum (ER) is involved in the production…

A person unlucky enough to have two specific gene variants is at significantly higher risk of developing multiple sclerosis (MS), according to a study. The research, which gave scientists insight into the processes that cause MS, also suggested that another mutation increased the effects of a known MS risk gene. The…

People with multiple sclerosis (MS) are more likely to develop kidney or bladder stones than those without MS, a new study concludes. The report, “Multiple sclerosis and nephrolithiasis: a matched-case comparative study,” appeared in the journal BJU International. Stone disease is highly lethal in patients with spinal cord injury (SCI), a condition that,…

Carol Hardaway was diagnosed with multiple sclerosis (MS) in 1990. After years of enduring relapses that brought episodes of complete blindness, numbness, tingling, debilitating fatigue, and short-term memory loss, the longtime resident of Texas — a state which offers Medicaid only to specific categories like low-income families, pregnant women, and…

Four newly published articles, the focused work of a group of researchers, evaluate the validity of four outcome measures commonly used in clinical trials of multiple sclerosis (MS) to set standards for such measures, the National MS Society recently reported. The effort by the Society-sponsored MS Outcome Assessments Consortium…

An extension of a Phase 3 clinical trial has shown that early treatment with Rebif (interferon beta-1a) in patients with initial manifestations of multiple sclerosis (MS) can prolong the time to a clinically definite multiple sclerosis (CDMS) diagnosis over five years. The study, “Subcutaneous interferon β-1a in…

The 2017 version of MuckFest MS, the five-kilometer fundraising mud-run series, will begin in a few weeks. The event, organized by the National Multiple Sclerosis Society and Event 360, features more than 18 obstacles in muddy settings. They include the swing set, muck off, skid mark, and more. Participants…